Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin‐2‐Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells

Xiong, Ying; Zhao, Qing; Gu, Liyan; Liu, Chun Ying; Wang, Chun

doi:10.1155/2018/8258246

Cited by 23 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here, we selected PC-9/GR, H1975 and H1650 cells to detect synergistic effects of SFI and gefitinib. Results suggested that SFI combined with gefitinib to inhibit cell proliferation, clonogenicity and induce apoptosis, which were consistant with the study conducted by Xiong Y, et al They documented that SFI increased chemotherapy sensitivity in cisplatin resistance of NSCLC cells through regulating cell cycle and initiating mitochondrial apoptosis 37. We further validated the underlying mechanism of SFI reversing gefitinib resistance was the inhibition of MAPK/SREBP1 pathway.…”

Section: Discussionsupporting

confidence: 85%

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

Pan¹,

Wang²,

Chen³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background:The clinical application of EGFR tyrosine kinase inhibitors is always accompanied by inevitable drug resistance. However, the mechanism remains elusive. In the present study, we investigate the involvement of MAPK/SREBP1 pathway in NSCLC gefitinib resistance and evaluate the synergistic effects of shenqi fuzheng injection (SFI) and gefitinib on NSCLC cells. Methods: To investigate the MAPK/SREBP1 pathway involved in gefitinib resistance, Western blotting was used to examine p-MEK, p-ERK and SREBP1 expression in PC-9 and PC-9/GR cells, MTT was used on cell proliferation, wound healing assay was used on cell migration. To detect the cooperative effects of SFI and gefitinib, clonogenic assay was used on cell proliferation. Apoptosis assay was analyzed by flow cytometry. Immunofluorescence was used to detect gefitinib binding to EGFR. Western blotting was used to detect whether SFI regulate the resistance to gefitinib via the suppression of MAPK/SREBP1 pathway. Results: Our results showed that MAPK/SREBP1 pathway mediated resistance to gefitinib in NSCLC cells. MAPK pathway was found to directly target SREBP1 and inhibition of SREBP1 increased gefitinib sensitivity. In addition, SFI showed cooperative anti-proliferation and pro-apoptosis impacts on gefitinib resistant cells via down-regulating MAPK/SREBP1 pathway. Moreover, the combination of SFI and gefitinib enhanced gefitinib binding to EGFR resulting in the restoration of sensitivity to gefitinib. Conclusions: Taken together, MAPK/SREBP1 pathway could be regarded as the potential treatment target for overcoming resistance to EGFR-TKIs in NSCLC and adjuvant therapy of SFI could be a potential therapeutic strategy for gefitinib resistant treatment.

show abstract

Section: Discussionsupporting

confidence: 85%

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

Pan¹,

Wang²,

Chen³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…[11]. Shenqi Fuzheng Injection also contained this ingredient and possessed growth inhibitory effect toward lung cancer cell line [12,13]. Several lines of evidence indicated that this compound was used to treat cardiovascular disease, rheumatism, and hemorrhage [14,15].…”

Section: Introductionmentioning

confidence: 99%

Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells

et al. 2019

View full text Add to dashboard Cite

In the present study, we investigated the potential effects of Isorhamnetin on the growth and metastasis of A549 human lung cancer cells, as well as the underlying mechanism. Treatment with Isorhamnetin exhibited a dose- and time-dependent inhibition on A549 cell proliferation. Furthermore, the cell adhesion and Transwell assay showed that treatment with Isorhamnetin (2.5, 5, and 10 μM) for 48 h resulted in a significant inhibition effect on cell adhesion, invasion and migration of A549 cells, depending on concentration, which was associated with the suppression of matrix metalloproteinase (MMP)-2 and MMP-9 activity and protein expression. Moreover, Isorhamnetin effectively suppressed the expressions of epithelial-to-mesenchymal transition (EMT) markers, as evidenced by the down-regulation of N-cadherin, vimentin and snail, as well as up-regulation of E-cadherin protein expression. Additionally, these inhibitions were mediated by interrupting AKT/ERK1/2 signaling pathways. Taken together, the results of the current study demonstrated that Isorhamnetin may become a good anti-metastastic agent against lung cancer A549 cell line by the suppression of EMT via interrupting Akt/ERK1/2 signaling pathway.

show abstract

“…Previous study also reported that SFI could re-sensitized chemotherapy to tumour cells through the initiation of mitochondrial apoptosis (Xiong et al. 2018). Based on the results of this meta-analysis, SFI could be recommended as complementary treatment for breast cancer patients.…”

Section: Discussionmentioning

confidence: 86%

ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis

Chen

Shan

2019

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: Shenqi FuZheng injection (SFI) has been suggested as a complementary treatment of chemotherapy in China. However, little is known about it in western countries.Objective: This study assesses the clinical effect of SFI combined with chemotherapy for breast cancer patients.Materials and methods: Both English and Chinese databases were searched covering the time period of 1999– 2018 for relevant studies comparing the effect of SFI plus chemotherapy treatment with chemotherapy alone in patients with breast cancer. Target outcomes concerning treatment effect, performance status, immune system and toxic effects were extracted and combined using Stata version 15.0 software. Quality assessment was performed using the Jadad scale.Results: Forty-nine trials were included based on certain selection criteria. Only seven studies were rated as high-quality publications. Results of meta-analysis showed that SFI intervention can significantly improve objective tumour response, performance status, NK, CD3+, CD4+ and CD4+/CD8+ ratio and reduce occurrence of leucopenia, thrombocytopenia, haemoglobin reduction, liver dysfunction, gastrointestinal reaction, nausea and vomiting, bone marrow suppression and ECG changes. However, no significant difference was found between SFI and the control group regarding CD8+ levels, and renal disorders.Discussion and conclusions: SFI intervention appeared to be effective in improving clinical efficacy, immune function and reducing toxicity when combined with chemotherapy for breast cancer. However, our findings still need verification by high-quality trials.

show abstract

Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin‐2‐Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells

Cited by 23 publications

References 46 publications

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells

ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis

Contact Info

Product

Resources

About